AOTMiT: Transparency Council on Parkinson's disease and lymphoma, among others

Agenda:

1. Preparation of a position paper on the evaluation of the drug Lecigon
   (levodopum + carbidopum + entacaponum) under the drug program B.90. "Treatment of motor disorders in the course of advanced Parkinson's disease"
   (ICD-10: G20).
2. Preparation of an opinion on the draft health policy program of the local government unit:
   "Program in the field of medical rehabilitation of the residents of the municipality of Kobierzyce for 2026-2029".
3. Preparation of an opinion on the draft health policy program of the local government unit:
   "Healthy heart of Lublin region - program of comprehensive cardiac rehabilitation (area of cardiovascular diseases)".
4. Preparation of an opinion on the draft health policy program of the local government unit:
   "Medical rehabilitation of residents of the municipality of Będzino for 2026-2028".
5. Preparation of an opinion on the active substance lenalidomide for the off-label indication
   (Annex C.84.d) in combination with:
   a) rituximab - for the treatment of adult patients with previously untreated grade 1-3a follicular lymphoma
   (ICD-10: C82.0, C82.1, C82.7);
   b) rituximab - for the treatment of adult patients with previously treated marginal zone lymphoma
   (ICD-10: C85.1, C85.7);
   c) rituximab - for the treatment of adult patients with relapsed or refractory mantle cell lymphoma
   (ICD-10: C85.7);
   d) tafasitamab - for the treatment of adult patients with either relapsed or refractory forms of diffuse large B-cell lymphoma (DLBCL) ineligible for autologous hematopoietic stem cell transplantation
   (ICD-10: C83).

Source: AOTMiT